Now looking for teams! No experience necessary - Lessons provided
Join the Kinsmen Club of Sackville for a fun filled evening for everyone involved!Read More
Did you know that your version of Internet Explorer is out of date?
To get the best possible experience using our website we recommend downloading one of the browsers below.
TORONTO (August 24, 2017) — Cystic Fibrosis Canada’s (CF Canada) Board of Directors has announced the resignation of Chief Executive Officer (CEO) Norma Beauchamp. Norma’s last day with the organization will be November 3, 2017.
“Norma has been a tireless advocate and leader for the cystic fibrosis community and for the work our organization does to support those living with CF,” said Mitch LePage, Chairman of the CF Canada Board of Directors. “The Board is grateful for her dedication and effort that has helped Cystic Fibrosis Canada make continued progress, and we are excited to see what this next chapter brings for all of us working to end CF.”
CF Canada continues to be one of the leading CF organizations internationally and now more than ever, the focus is on ending CF. Thanks to Norma’s leadership over the past three years, the organization is well-positioned to continue this work and progress moving into the future under its next leader. The tenacity and commitment of the CF Canada community throughout its history have and will ultimately continue to be the reason we are closer than ever to finding a cure or control for this disease.
“As I approach the end of my third year as CEO, I have reflected on my role with the organization in a personal and professional context. It is time for me to make changes in my life, and I knew in order to do this I had to do what was best for CF Canada’s future and strategic direction. I discussed this with the Board, and notified them of my resignation.
“I intend to remain involved with the community through events like our walk and volunteering opportunities. This cause will remain close to my heart for the rest of my life, as I’m passionate about ending CF for my nephew and every family affected by this disease. I want to extend my deepest thanks to every person in this community for allowing me to fill this role and for supporting our work these past three years. It’s been a great honour.”
CF Canada is committed to ensuring a smooth and effective transition as a new CEO is selected over the coming months. Work will continue on the many projects in progress such as the OneCFocus 2020 strategic direction, year-end giving campaign, the CFIT (Cystic Fibrosis Individualized Therapy) Program, the Walk to Make CF History and more. Above all, CF Canada remains focused on the vision of a world without cystic fibrosis and looks forward to the future of the organization.
About cystic fibrosis
Cystic fibrosis is the most common fatal genetic disease affecting Canadian children and young adults. It is a multi-system disease that affects mainly the lungs and the digestive system. In the lungs, where the effects are most devastating, a build-up of thick mucus causes severe respiratory problems. Mucus also builds up in the digestive tract, making it difficult to digest and absorb nutrients from food. As improved therapies have helped to address the malnutrition issues, most deaths related to cystic fibrosis are now due to lung disease. There is no cure. In Canada on average, one baby in 3,500 suffers from cystic fibrosis while in Québec, the average is one baby in 2,500.
Cystic Fibrosis Canada
Cystic Fibrosis Canada is one of the three principal charitable organizations committed to finding a cure for cystic fibrosis and is an internationally recognized leader in funding research, innovation and clinical care. Cystic Fibrosis Canada has invested more funding in life-saving CF research and care than any other non-governmental agency in Canada. Since 1960, Cystic Fibrosis Canada has invested more than $244 million in leading research, care and advocacy, resulting in one of the world’s highest survival rates for Canadians living with cystic fibrosis.
For more information and media requests, please contact:
416-485-9149 ext. 248